All In MedTech

Device Trial Radar · NCT05538754

Post-Market Evaluation of the EVO ICL

Last checked: Nov 20, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

205

Actual

Start

Sep 23, 2022

Primary completion

Sep 21, 2023

Study completion Oct 4, 2023

Sponsor

Lead sponsor
Staar Surgical CompanyNot on our public-company list
Sponsor type
Industry
First posted
Sep 14, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 21 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the rate of early intraocular pressure (IOP) increases following implantation of EVO/EVO+ Implantable Collamer Lens (ICL).

Conditions

  • Myopia
  • Myopic Astigmatism

Interventions

  • EVO ICLDevice

    The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Elevated Intraocular Pressure (IOP) in Primary Eyes ≥ 30 mmHgTime frame: 1-6 hours postoperatively
  2. Elevated Intraocular Pressure (IOP) in Primary Eyes ≥ 40 mmHGTime frame: 1-6 hours postoperatively

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Aloha Laser Vision, LLC

    Honolulu, Hawaii

  • Durrie Vision

    Overland Park, Kansas

  • Kugler Vision, PC

    Omaha, Nebraska

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.